<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814086</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-9921</org_study_id>
    <secondary_id>NCI-2009-00624</secondary_id>
    <secondary_id>GOG-9921</secondary_id>
    <secondary_id>CDR0000629746</secondary_id>
    <secondary_id>GOG-9921</secondary_id>
    <secondary_id>GOG-9921</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00814086</nct_id>
  </id_info>
  <brief_title>Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer</brief_title>
  <official_title>A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of cisplatin given together&#xD;
      with paclitaxel in treating patients with stage IIB, stage IIC, stage III, or stage IV&#xD;
      ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer. Drugs&#xD;
      used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      more than one drug (combination chemotherapy) and giving them in different ways may kill more&#xD;
      tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the feasibility of intraperitoneal (IP) cisplatin and intravenous (IV)&#xD;
      paclitaxel followed by IP paclitaxel in patients with stage IIB, IIC, III, or IV ovarian&#xD;
      epithelial, fallopian tube, or primary peritoneal cavity cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the toxicity of this regimen in these patients. II. Determine the types of surgical&#xD;
      and catheter complications that may occur after surgery or during the course of treatment in&#xD;
      these patients.&#xD;
&#xD;
      III. Estimate the response rate in patients with measurable disease treated with this&#xD;
      regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive paclitaxel IV over 3 hours and cisplatin intraperitoneally (IP) on day 1 and&#xD;
      paclitaxel IP on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who have at least 1 dose-limiting toxicity or delay in therapy for more than 2 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade of toxicity as assessed by Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to the catheter or the surgical placement of the catheter</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response (partial or complete) assessed by Response Evaluation Criteria for Solid Tumors (RECIST)</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Chemotherapeutic Agent Toxicity</condition>
  <condition>Endometrial Adenocarcinoma</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Gastrointestinal Complication</condition>
  <condition>Malignant Ovarian Mixed Epithelial Tumor</condition>
  <condition>Neurotoxicity Syndrome</condition>
  <condition>Ovarian Brenner Tumor</condition>
  <condition>Ovarian Clear Cell Cystadenocarcinoma</condition>
  <condition>Ovarian Mucinous Cystadenocarcinoma</condition>
  <condition>Ovarian Serous Cystadenocarcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Stage II Ovarian Cancer</condition>
  <condition>Stage III Ovarian Cancer</condition>
  <condition>Stage IV Ovarian Cancer</condition>
  <condition>Undifferentiated Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (paclitaxel, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 3 hours and cisplatin intraperitoneally (IP) on day 1 and paclitaxel IP on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV or intraperitoneally</description>
    <arm_group_label>Treatment (paclitaxel, cisplatin)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>TAX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given intraperitoneally</description>
    <arm_group_label>Treatment (paclitaxel, cisplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal&#xD;
             cavity cancer&#xD;
&#xD;
               -  Stage IIB, IIC, III, or IV disease&#xD;
&#xD;
               -  Optimal or suboptimal residual disease after debulking surgery within the past 12&#xD;
                  weeks&#xD;
&#xD;
                    -  Appropriate tissue for histologic evaluation available&#xD;
&#xD;
          -  The following histologic epithelial cell types are eligible:&#xD;
&#xD;
               -  Serous adenocarcinoma&#xD;
&#xD;
               -  Endometrioid adenocarcinoma&#xD;
&#xD;
               -  Mucinous adenocarcinoma&#xD;
&#xD;
               -  Undifferentiated carcinoma&#xD;
&#xD;
               -  Clear cell adenocarcinoma&#xD;
&#xD;
               -  Mixed epithelial carcinoma&#xD;
&#xD;
               -  Transitional cell carcinoma&#xD;
&#xD;
               -  Malignant Brenner tumor&#xD;
&#xD;
               -  Adenocarcinoma not otherwise specified&#xD;
&#xD;
               -  Carcinosarcoma&#xD;
&#xD;
          -  No ovarian epithelial carcinoma of low malignant potential (borderline carcinomas)&#xD;
&#xD;
          -  No synchronous primary endometrial cancer or a history of primary endometrial cancer&#xD;
             unless all of the following conditions are met:&#xD;
&#xD;
               -  Stage ≤ IB disease&#xD;
&#xD;
               -  No more than superficial myometrial invasion, without vascular or lymphatic&#xD;
                  invasion&#xD;
&#xD;
               -  No poorly differentiated subtypes, including papillary serous, clear cell, or&#xD;
                  other FIGO grade 3 lesion&#xD;
&#xD;
          -  GOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  SGOT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Audiograms required after study chemotherapy courses 3 and 6 for patients with hearing&#xD;
             loss, or who are experiencing tinnitus during study therapy&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  None of the following:&#xD;
&#xD;
               -  Septicemia&#xD;
&#xD;
               -  Severe infection requiring parenteral antibiotics&#xD;
&#xD;
               -  Malnutrition requiring parenteral hyperalimentation&#xD;
&#xD;
               -  Acute hepatitis&#xD;
&#xD;
               -  Any other major medical conditions expected to interfere with completion of&#xD;
                  protocol therapy&#xD;
&#xD;
          -  No active bleeding&#xD;
&#xD;
          -  No circumstances that would prohibit completion of study therapy or required follow-up&#xD;
&#xD;
          -  No history of allergic reaction to polysorbate 80 (e.g., etoposide or vitamin E)&#xD;
&#xD;
          -  No other invasive malignancies, except for nonmelanoma skin cancer or other specific&#xD;
             malignancies within the past 5 years, or whose previous cancer treatment&#xD;
             contraindicates this protocol therapy&#xD;
&#xD;
          -  No unstable angina or myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Abnormal cardiac conduction (e.g., bundle branch block or heart block) that has&#xD;
                  been stable for the past 6 months allowed&#xD;
&#xD;
          -  No prior targeted therapy for the management of ovarian epithelial or primary&#xD;
             peritoneal cavity cancer including, but not limited to, the following:&#xD;
&#xD;
               -  Vaccines&#xD;
&#xD;
               -  Antibodies&#xD;
&#xD;
               -  Tyrosine kinase inhibitors&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  No prior hormonal therapy for the management of epithelial ovarian or primary&#xD;
             peritoneal cavity cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Dizon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Hospital University Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulsa Cancer Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 20, 2008</study_first_submitted>
  <study_first_submitted_qc>December 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <last_update_submitted>December 29, 2014</last_update_submitted>
  <last_update_submitted_qc>December 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Cystadenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Brenner Tumor</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

